[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100511124":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":31,"responsibleParty":204,"collaborators":19,"id":206,"slug":207,"hasResults":208,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":208,"sex":214,"minAge":215,"maxAge":19,"enrollmentInfo":216,"targetDuration":19,"studyType":219,"phases":220,"briefSummary":222,"conditions":223,"keywords":19,"overallStatus":34,"whyStopped":19,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":234},{"fullName":5,"class":6},"Octapharma","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Nuwiq","EXPERIMENTAL","All patients receiving Nuwiq (recombinant FVIII). Nuwiq will be administered intravenously in accordance with the relevant prescribing information. Treatment will be repeated as necessary every 8-24 hours until adequate wound healing, then - if required - for at least another 7 days to maintain FVIII plasma levels of 30-60 IU\u002FdL.",[13],"Drug: Nuwiq",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Nuwiq is a purified B-domain-deleted FVIII glycoprotein synthesised by a genetically engineered human embryonic kidney cell line (HEK 293F).",[9],null,[21],{"name":22,"affiliation":23,"role":24},"Shveta Gupta, MD","Arnold Palmer Hospital for Children","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":19,"email":30},"Sigurd Knaub, PhD","CONTACT","+41 554512141","Sigurd.Knaub@octapharma.com",[32,46,56,66,76,84,94,102,110,121,129,139,147,155,165,175,185,193],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":19},"UT Southwestern Medical Center","RECRUITING","Dallas","Texas","75390","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-96.80667,32.78306,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":19,"zip":19,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":19},"University Hospital Centre Zagreb","Zagreb","Croatia","HR",{"type":41,"coordinates":52},[53,54],15.97798,45.81444,{"lat":54,"lon":53},{"facility":57,"status":34,"city":58,"state":19,"zip":19,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":19},"Helsinki University Hospital","Helsinki","Finland","FI",{"type":41,"coordinates":62},[63,64],24.93545,60.16952,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":19,"zip":19,"country":69,"countryCode":70,"cosmosGeoPoint":71,"geoPoint":75,"contacts":19},"CHU de Nantes Hôtel-Dieu","Nantes","France","FR",{"type":41,"coordinates":72},[73,74],-1.55336,47.21725,{"lat":74,"lon":73},{"facility":77,"status":34,"city":78,"state":19,"zip":19,"country":69,"countryCode":70,"cosmosGeoPoint":79,"geoPoint":83,"contacts":19},"CHRU de Tours","Tours",{"type":41,"coordinates":80},[81,82],0.70398,47.39484,{"lat":82,"lon":81},{"facility":85,"status":34,"city":86,"state":19,"zip":19,"country":87,"countryCode":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":19},"Vivantes Klinikum im Friedrichshein (KFH)","Berlin","Germany","DE",{"type":41,"coordinates":90},[91,92],13.41053,52.52437,{"lat":92,"lon":91},{"facility":95,"status":34,"city":96,"state":19,"zip":19,"country":87,"countryCode":88,"cosmosGeoPoint":97,"geoPoint":101,"contacts":19},"Gerinnungszentrum Rhein-Ruhr","Duisburg",{"type":41,"coordinates":98},[99,100],6.76516,51.43247,{"lat":100,"lon":99},{"facility":103,"status":34,"city":104,"state":19,"zip":19,"country":87,"countryCode":88,"cosmosGeoPoint":105,"geoPoint":109,"contacts":19},"Universitätsklinikum Hamburg Eppendorf (UKE)","Hamburg",{"type":41,"coordinates":106},[107,108],9.99302,53.55073,{"lat":108,"lon":107},{"facility":111,"status":34,"city":112,"state":113,"zip":19,"country":114,"countryCode":115,"cosmosGeoPoint":116,"geoPoint":120,"contacts":19},"Christian Medical College Vellore","Vellore","Tamil Nadu","India","IN",{"type":41,"coordinates":117},[118,119],79.13255,12.9184,{"lat":119,"lon":118},{"facility":122,"status":34,"city":123,"state":19,"zip":19,"country":114,"countryCode":115,"cosmosGeoPoint":124,"geoPoint":128,"contacts":19},"St. John's Medical College Hospital","Bengaluru",{"type":41,"coordinates":125},[126,127],77.59369,12.97194,{"lat":127,"lon":126},{"facility":130,"status":34,"city":131,"state":19,"zip":19,"country":132,"countryCode":133,"cosmosGeoPoint":134,"geoPoint":138,"contacts":19},"Azienda Ospedaliera Pugliese Ciaccio","Catanzaro","Italy","IT",{"type":41,"coordinates":135},[136,137],16.60086,38.88247,{"lat":137,"lon":136},{"facility":140,"status":34,"city":141,"state":19,"zip":19,"country":132,"countryCode":133,"cosmosGeoPoint":142,"geoPoint":146,"contacts":19},"Azienda Ospedaliero Universitaria Careggi - Centro Emofilia","Florence",{"type":41,"coordinates":143},[144,145],11.24626,43.77925,{"lat":145,"lon":144},{"facility":148,"status":34,"city":149,"state":19,"zip":19,"country":132,"countryCode":133,"cosmosGeoPoint":150,"geoPoint":154,"contacts":19},"Centro Trombosi e Malattie Emorragiche, ITCCS Humanitas Research Hospital","Milan",{"type":41,"coordinates":151},[152,153],9.18951,45.46427,{"lat":153,"lon":152},{"facility":156,"status":34,"city":157,"state":19,"zip":19,"country":158,"countryCode":159,"cosmosGeoPoint":160,"geoPoint":164,"contacts":19},"Centre for Haemopilia, Institute for transfusion medicine of Republic of North Macedonia","Skopje","North Macedonia","MK",{"type":41,"coordinates":161},[162,163],21.43141,41.99646,{"lat":163,"lon":162},{"facility":166,"status":34,"city":167,"state":19,"zip":19,"country":168,"countryCode":169,"cosmosGeoPoint":170,"geoPoint":174,"contacts":19},"Clinical Center for Serbia Belgrade","Belgrade","Serbia","RS",{"type":41,"coordinates":171},[172,173],20.46513,44.80401,{"lat":173,"lon":172},{"facility":176,"status":34,"city":177,"state":19,"zip":19,"country":178,"countryCode":179,"cosmosGeoPoint":180,"geoPoint":184,"contacts":19},"Hospital Universitario La Paz","Madrid","Spain","ES",{"type":41,"coordinates":181},[182,183],-3.70256,40.4165,{"lat":183,"lon":182},{"facility":186,"status":34,"city":187,"state":19,"zip":19,"country":178,"countryCode":179,"cosmosGeoPoint":188,"geoPoint":192,"contacts":19},"Hospital Universitario Virgen del Rocio","Seville",{"type":41,"coordinates":189},[190,191],-5.97317,37.38283,{"lat":191,"lon":190},{"facility":194,"status":195,"city":196,"state":19,"zip":19,"country":197,"countryCode":198,"cosmosGeoPoint":199,"geoPoint":203,"contacts":19},"St. James's University Hospital","NOT_YET_RECRUITING","Leeds","United Kingdom","UK",{"type":41,"coordinates":200},[201,202],-1.54785,53.79648,{"lat":202,"lon":201},{"type":205,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100511124","phase-4-nuwiq-for-perioperative-management-of-patients-with-haemophilia-a-on-emicizumab-regular-prophylaxis-study-100511124",false,"NCT05935358","Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study","Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)","NuPOWER","Inclusion Criteria:\n\n* Severe haemophilia A (FVIII activity \\[FVIII:C\\] \\\u003C1%) according to medical history\n* Male patients at least 12 years of age\n* Previous treatment with any FVIII product(s) for at least 150 exposure days\n* On regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring FVIII treatment\n* Freely given written informed consent of the patient, or parent\u002Flegal representative where applicable, obtained in accordance with local regulations\n\nExclusion Criteria:\n\n* Coagulation disorder other than haemophilia A\n* Present or past FVIII inhibitor (≥0.6 Bethesda units \\[BU\\]\u002FmL) according to medical history\n* Severe liver or kidney disease (alanine aminotransferase \\[ALT\\] and\u002For aspartate aminotransferase \\[AST\\] levels \\>5 times the upper limit of normal; or creatinine \\>120 μmol\u002FL)\n* Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)\n* Already had surgery in this study\n* Current participation in another interventional clinical trial\n* Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit","MALE","12 Years",{"count":217,"type":218},28,"ESTIMATED","INTERVENTIONAL",[221],"PHASE4","Recombinant factor VIII for the prevention of bleeding in patients with severe haemophilia A undergoing major surgery while receiving emicizumab prophylaxis",[224],"Severe Hemophilia A","2026-05-08",{"date":227,"type":228},"2026-05-12","ACTUAL",{"date":230,"type":228},"2023-11-28",{"date":232,"type":218},"2026-09",{"name":5,"class":6},18]